SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 29, 2001
ONYX Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware 0-28298 94-3154463
(State of jurisdiction) (Commission File No.) (IRS Employer
Identification No.)
3031 Research Drive
Richmond, CA 94806
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (510) 222-9700
Item 5. Other Events
On January 29, 2001 we announced that we had entered into a strategic process
development and manufacturing relationship with XOMA (US) LLC, a Delaware
limited liability company (Nasdaq: XOMA) of Berkeley, California. Under the
terms of the multiyear agreement, XOMA will develop a large-scale process and
will manufacture CI-1042 for clinical trials and large-scale production. In
return, we will provide XOMA with an upfront payment; support for development
efforts on the process scale-up and production of bulk drug materials; and
milestone payments associated with attainment of large-scale production.
The terms and conditions of the relationship with Xoma are set forth in the
Process Development and Manufacturing Agreement dated January 29, 2001,
attached hereto as Exhibit 99.1, which is incorporated herein by reference.
The press release issued by Onyx, dated January 29, 2001, entitled "Onyx and
XOMA Announce Strategic Process Development and Manufacturing Agreement" is
attached as Exhibit C to Exhibit 99.1.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
(c) Exhibits.
EXHIBIT
NUMBER DESCRIPTION
99.1* Process Development and Manufacturing Agreement between XOMA
(US) LLC and Onyx Pharmaceuticals, Inc., dated January 29, 2001.
*Confidential treatment requested.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ONYX Pharmaceuticals, Inc.
Dated: February 22, 2001 By: /s/ HOLLINGS C. RENTON
----------------------------------------
Hollings C. Renton
Chairman of the Board,
President and Chief Executive
Officer
Dated: February 22, 2001 By: /s/ MARILYN WORTZMAN
----------------------------------------
Marilyn Wortzman
Controller
3
EXHIBIT INDEX
EXHIBIT
NUMBER DESCRIPTION
99.1* Process Development and Manufacturing Agreement between XOMA
(US) LLC and Onyx Pharmaceuticals, Inc., dated January 29, 2001.
*Confidential treatment requested.
4